Generic opportunity for Alchemia
Friday, 13 March, 2009
Alchemia’s manufacturing partner Dr Reddy’s Laboratories has filed an abbreviated new drug application with the US FDA for a generic version of fondaparinux, used to prevent blood clots.
Fondaparinux is currently marketed by GlaxoSmithKline under the brand name Atrixa, which came off patent in 2002.
No other company has filed an application for a generic in that time as fondaparinux is a difficult molecule to synthesise, Alchemia said.
It is hoped the FDA will review the application within six months of filing under a priority review system.
Does exercise really extend lifespan? It's complicated
Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...
Nature helps to relieve physical pain
Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
